一个由IMiD和基尿素控制的SCD病例
Ashrei Bayewitz1, Sai Shalini Pillarisetty2, Fatemeh Moeini Nia3
1South Brooklyn Health, 2601 Ocean Parkway, Brooklyn, NY, 11235, USA. ashreibay@gmail.com.
免疫调节剂药物 (IMiDs) 和基尿素在状细胞病 (SCD) 方面表现有前途. 在严重的SCD患者中,长期治疗导致了持续的SCD缓解,这表明了潜在的治疗益处.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 状细胞疾病 (SCD) 是一种使人虚弱的遗传血液疾病.
- 已知免疫调节药物 (IMiDs) 会增加胎儿血红蛋白 (HbF) 水平.
- 目前,IMIDs尚未被批准用于SCD治疗.
研究的目的:
- 报告一个严重的SCD和多发性骨髓瘤 (MM) 的病例,用IMIDs和基尿素治疗.
- 评估这种联合治疗对SCD缓解的长期疗效.
主要方法:
- 一名患有严重SCD和MM的患者接受了IMiDs和氧尿素的组合.
- 治疗持续时间超过6年.
- 在整个治疗期间,对SCD状态和HbF水平进行了监测.
主要成果:
- 患者实现了SCD的持续缓解.
- 在治疗过程中,HbF的产生得到了增强.
- 结合疗法在长期内被耐受.
结论:
- 长期使用IMiDs和基尿素的治疗可以导致持续的SCD缓解.
- 这一案例凸显了IMiDs作为SCD治疗选择的潜力.
- 需要进一步的研究来探索SCD管理中的IMiD.
更多相关视频
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
08:23Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
相关概念视频
iPS Cell Differentiation
Multiple Allele Traits
Cystic Fibrosis: Management
Sinus disease and chronic...
Regulation of Hematopoietic Stem Cells
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
